KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Debt to Equity (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Debt to Equity for 17 consecutive years, with $2.44 as the latest value for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 19.54% to $2.44 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.44, a 19.54% decrease, with the full-year FY2025 number at $2.44, down 19.54% from a year prior.
  • Debt to Equity was $2.44 for Q4 2025 at Bristol Myers Squibb, down from $2.64 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $959.95 in Q1 2024 to a low of -$35.98 in Q2 2024.
  • A 5-year average of $180.01 and a median of $2.83 in 2024 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: skyrocketed 70320.68% in 2021, then tumbled 161.32% in 2022.
  • Bristol Myers Squibb's Debt to Equity stood at -$35.14 in 2021, then surged by 97.1% to -$1.02 in 2022, then soared by 13477.37% to $136.21 in 2023, then tumbled by 97.78% to $3.03 in 2024, then decreased by 19.54% to $2.44 in 2025.
  • Per Business Quant, the three most recent readings for BMY's Debt to Equity are $2.44 (Q4 2025), $2.64 (Q3 2025), and $168.44 (Q2 2025).